Hereditary Angioedema Market

Hereditary Angioedema Market (Drug Class - C1 Esterase Inhibitor (Cinryze, Berinert, and Ruconest), Selective Bradykinin B2 Receptor Antagonist (Firazyr), and Kallikrein Inhibitor (Kalbitor); Route of Administration - Intravenous, Subcutaneous Injection, and Oral; Distribution Channel - Hospital Pharmacies and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Rep Id : TMRGL17135
  • Published On : Aug 2017
  • No. of Pages : 153
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Market Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
            4.3.4. Trends
     4.4. Hereditary Angioedema Market Analysis and Forecast, 2017 – 2025
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Market Outlook
     4.6. Porter’s five forces analysis
     4.7. Value Chain Analysis
     4.8. Pipeline Analysis
     4.9. Orphan Drug Exclusivity Details
     4.10. Disease Overview

5. Global Hereditary Angioedema Market Analysis and Forecasts, By Drug Class
     5.1. Introduction & Definition
     5.2. Key Findings
     5.3. Key Trends
     5.4. Market Size (US$ Mn) Forecast By Drug Class
            5.4.1. C1 esterase inhibitor
                       5.4.1.1. Cinryze
                       5.4.1.2. Berinert
                       5.4.1.3. Ruconest
            5.4.2. Selective bradykinin B2 receptor antagonist
                       5.4.2.1. Firazyr
            5.4.3. Kallikrein inhibitor
                       5.4.3.1. Kalbitor
     5.4.4. Others
                       5.4.4.1. Conventional Drugs
                       5.4.4.2. Pipeline Drugs
     5.5. Comparison Matrix
     5.6. Market Attractiveness By Drug Class

6. Global Hereditary Angioedema Market Analysis and Forecasts, By Route of Administration
     6.1. Introduction & Definition
     6.2. Key Findings 
     6.3. Market Size (US$ Mn) Forecast By Route of Administration
            6.3.1. Intravenous
            6.3.2. Subcutaneous injection
            6.3.3. Oral
     6.4. Comparison Matrix
     6.5. Market Attractiveness By Route of Administration

7. Global Hereditary Angioedema Market Analysis and Forecasts, By Distribution Channel
     7.1. Introduction & Definition
     7.2. Key Findings 
     7.3. Key Trends
     7.4. Market Size (US$ Mn) Forecast By Distribution Channel
     7.4.1. Hospital pharmacies
            7.4.2. Retail pharmacies
            7.4.3. Others
     7.5. Comparison Matrix
     7.6. Market Attractiveness By Distribution Channel

8. Global Hereditary Angioedema Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Key Trends
     8.3. Market Size (US$ Mn) Forecast By Region
            8.3.1. North America
            8.3.2. Europe
            8.3.3. Rest of the World
     8.4. Market Attractiveness By Region

9. North America Hereditary Angioedema Market Analysis and Forecast
     9.1. Key Findings
     9.2. Policies and Regulations
     9.3. Market Overview
     9.4. Market Size (US$ Mn) Forecast By Drug Class
            9.4.1. C1 esterase inhibitor
                       9.4.1.1. Cinryze
                       9.4.1.2. Berinert
                       9.4.1.3. Ruconest
            9.4.2. Selective bradykinin B2 receptor antagonist
                       9.4.2.1. Firazyr
            9.4.3. Kallikrein inhibitor
                       9.4.3.1. Kalbitor
            9.4.4. Others
                       9.4.4.1. Conventional Drugs
                       9.4.4.2. Pipeline Drugs
     9.5. Market Size (US$ Mn) Forecast By Route of Administration
            9.5.1. Intravenous
            9.5.2. Subcutaneous injection
            9.5.3. Oral
     9.6. Market Size (US$ Mn) Forecast By Distribution Channel
            9.6.1. Hospital pharmacies
            9.6.2. Retail pharmacies
            9.6.3. Others
     9.7. Market Size by Value (US$ Mn) Forecast, By Country
            9.7.1. U.S.
            9.7.2. Canada
     9.8. Market Attractiveness Analysis 
            9.8.1. By Drug Class
            9.8.2. By Route of Administration
            9.8.3. By Distribution Channel
            9.8.4. By Country

10.  Europe Hereditary Angioedema Market Analysis and Forecast
     10.1. Key Findings
     10.2. Policies and Regulations
     10.3. Market Overview
     10.4. Market Size (US$ Mn) Forecast By Drug Class
            10.4.1. C1 esterase inhibitor
                       10.4.1.1. Cinryze
                       10.4.1.2. Berinert
                       10.4.1.3. Ruconest
            10.4.2. Selective bradykinin B2 receptor antagonist
                       10.4.2.1. Firazyr
            10.4.3. Others
                       10.4.3.1. Conventional Drugs
                       10.4.3.2. Pipeline Drugs
     10.5. Market Size (US$ Mn) Forecast By Route of Administration
            10.5.1. Intravenous
            10.5.2. Subcutaneous injection
            10.5.3. Oral
     10.6. Market Size (US$ Mn) Forecast By Distribution Channel
            10.6.1. Hospital pharmacies
            10.6.2. Retail pharmacies
            10.6.3. Others
     10.7. Market Size by Value (US$ Mn) Forecast, By Country
            10.7.1. Germany
            10.7.2. U.K.
            10.7.3. France
            10.7.4. Spain
            10.7.5. Italy
            10.7.6. Rest of Europe
     10.8. Market Attractiveness Analysis 
            10.8.1. By Drug Class
            10.8.2. By Route of Administration
            10.8.3. By Distribution Channel
            10.8.4. By Country / Sub-region

11. Rest of The World Hereditary Angioedema Market Analysis and Forecast
     11.1. Key Findings
     11.2. Policies and Regulations
     11.3. Market Overview
     11.4. Market Size (US$ Mn) Forecast By Drug Class
            11.4.1. C1 esterase inhibitor
                       11.4.1.1. Cinryze
                       11.4.1.2. Berinert
                       11.4.1.3. Ruconest
            11.4.2. Selective bradykinin B2 receptor antagonist
                       11.4.2.1. Firazyr
            11.4.3. Kallikrein inhibitor
                       11.4.3.1. Kalbitor
            11.4.4. Others
                       11.4.4.1. Conventional Drugs
                       11.4.4.2. Pipeline Drugs
     11.5. Market Size (US$ Mn) Forecast By Route of Administration
            11.5.1. Intravenous
            11.5.2. Subcutaneous injection
            11.5.3. Oral
     11.6. Market Size (US$ Mn) Forecast By Distribution Channel
            11.6.1. Hospital pharmacies
            11.6.2. Retail pharmacies
            11.6.3. Others
     11.7. Market Attractiveness Analysis 
            11.7.1. By Drug Class
            11.7.2. By Route of Administration
            11.7.3. By Distribution Channel

12.  Competition Landscape
     12.1. Market Share Analysis
     12.2. Market Player – Competition Matrix (By Tier and Size of companies)
     12.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            12.3.1. Shire plc
                       12.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                       12.3.1.2. Product Portfolio
                       12.3.1.3. SWOT Analysis
                       12.3.1.4. Financial Overview
                       12.3.1.5. Strategic Overview
            12.3.2. CSL Limited
                       12.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                       12.3.2.2. Product Portfolio
                       12.3.2.3. SWOT Analysis
                       12.3.2.4. Financial Overview
                       12.3.2.5. Strategic Overview
            12.3.3. Pharming Group NV
                       12.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                       12.3.3.2. Product Portfolio
                       12.3.3.3. SWOT Analysis
                       12.3.3.4. Financial Overview
                       12.3.3.5. Strategic Overview
            12.3.4. Ionis Pharmaceuticals, Inc.
                       12.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                       12.3.4.2. Product Portfolio
                       12.3.4.3. SWOT Analysis
                       12.3.4.4. Financial Overview
                       12.3.4.5. Strategic Overview
            12.3.5. iBio Inc.
                       12.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                       12.3.5.2. Product Portfolio
                       12.3.5.3. SWOT Analysis
                       12.3.5.4. Financial Overview
                       12.3.5.5. Strategic Overview
            12.2.6. BioCryst Pharmaceuticals, Inc.
                       12.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                       12.3.6.2. Product Portfolio
                       12.3.6.3. SWOT Analysis
                       12.3.6.4. Financial Overview
                       12.3.6.5. Strategic Overview

List of Tables

Table 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, By Phase II and Phase I
Table 03: Pipeline Analysis, By Preclinical Trial (1/2)
Table 04: Pipeline Analysis, By Preclinical Trial (2/2)
Table 05: Orphan Drug Exclusivity (1/3)
Table 06: Orphan Drug Exclusivity (2/3)
Table 07: Orphan Drug Exclusivity (3/3)
Table 08: Disease Overview by Type of HAE
Table 09: Reported and Estimated Cases of HAE, By Country
Table 10: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2015–2025
Table 12: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Others, 2015–2025
Table 13: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 14: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 15: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 16: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 17: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2015–2025
Table 18: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - Others, 2015–2025
Table 19: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 20: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 22: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 esterase inhibitor, 2015–2025
Table 24: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Others, 2015–2025
Table 25: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 26: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 27: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 28: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 29: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - C1 Esterase Inhibitor, 2015–2025
Table 30: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - Others, 2015–2025
Table 31: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 32: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Figures

Figure 01: Global Hereditary Angioedema, by Drug Class, Market Size (US$ Mn), 2016 (A)
Figure 02: Global Hereditary Angioedema Market Revenue (%), by Route of Administration, 2016 (A)
Figure 03: Global Hereditary Angioedema Market Revenue (%), by Region, 2016 (A)
Figure 04: Opportunity Map, By Drug Class 2016
Figure 05: Opportunity Map, By Route of Administration and Distribution Channel 2016
Figure 06: Global Hereditary Angioedema Market - Key Industry Developments
Figure 07: Global Hereditary Angioedema Market – Key Drivers and Restraints
Figure 08: Global Hereditary Angioedema Market - Opportunity Analysis
Figure 09: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, 2015–2025
Figure 10: Porter’s Five Forces Analysis
Figure 11: Global Hereditary Angioedema Market - Value Chain Analysis
Figure 12: Market Value Share, by Drug Class (2016)
Figure 13: Market Value Share, by Route of Administration (2016)
Figure 14: Market Value Share, by Distribution Channel (2016)
Figure 15: Global Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 16: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2015–2025
Figure 17: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2015–2025
Figure 18: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2015–2025
Figure 19: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others,       2015–2025
Figure 20: Global Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 21: Global Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 22: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2015–2025
Figure 23: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2015–2025
Figure 24: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
Figure 25: Global Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 26: Global Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 27: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 28: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 29: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 30: Global Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 31: Global Hereditary Angioedema Market Value Share Analysis, by Region, 2016 and 2025
Figure 32: Global Hereditary Angioedema Market Attractiveness Analysis, by Region
Figure 33: North America Hereditary Angioedema Market Size (US$ Mn) Forecast, 2017–2025
Figure 34: North America Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 35: North America Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 36: North America Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 37: North America Hereditary Angioedema Market Value Share Analysis, by Country, 2016 and 2025
Figure 38: North America Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 39: North America Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 40: North America Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
Figure 41: North America Market Attractiveness Analysis, by Country
Figure 42: Europe Hereditary Angioedema Market Size (US$ Mn) Forecast, 2017–2025
Figure 43: Europe Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 44: Europe Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 45: Europe Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 46: Europe Hereditary Angioedema Market Value Share Analysis, by Country, 2016 and 2025
Figure 47: Europe Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 48: Europe Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 49: Europe Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
Figure 50: Europe Market Attractiveness Analysis, by Country
Figure 51: Rest of the World Hereditary Angioedema Market Size (US$ Mn) Forecast, 2015–2025
Figure 52: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 53: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 54: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 55: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 56: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 57: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
Figure 58: Global Hereditary Angioedema Market Share Analysis, by Company (2016)
Figure 59: Shire Plc. Breakdown of Net Sales, by Segment, 2016
Figure 60: Shire Plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 61: CSL Limited Breakdown of Net Sales, by Region, 2015
Figure 62: CSL Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2012–2015
Figure 63: Pharming Group NV Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 64: Ionis Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 65: iBio, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 66: BioCryst Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016